Intrathecal injections of non-peptide oxytocin receptor agonists, WAY 267,464 and TC OT 39, induce significant anti-hyperalgesia in both male and female rats with inflammatory pain

Articles in Press

Document Type : Original Article

Authors

1 Department of Anesthesiology, Taipei Veterans General Hospital, Taipei, Taiwan

2 Department of Anesthesiology, School of Medicine and Institute of Clinical Nursing, School of Nursing, National Yung Ming Chiao Tung University, Taipei, Taiwan

3 Department of Anesthesiology, National Defense Medical Center, Taipei, Taiwan

4 Department of Pharmacology, National Defense Medical Center, Taipei, Taiwan

5 Department of Neurological Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

10.22038/ijbms.2025.86093.18615

Abstract

Objective(s): Hyperalgesia is a clinical condition related to chronic pain in which patients experience increased nociceptive sensitivity. Intrathecal oxytocin has been shown to induce significant anti-hyperalgesia in both rodents and humans. However, in our previous studies, we demonstrated a clear sex difference in oxytocin’s effects at the spinal level in rodents. We suggested that this sex difference could be partially due to the higher expression of the oxytocin-degrading enzyme, insulin-regulated aminopeptidase (IRAP), in the spinal cord of females. Thus, we aimed to evaluate non-peptide oxytocin receptor (OTR) agonists, which we speculated could effectively reduce inflammatory hyperalgesia in both sexes due to their resistance to IRAP degradation.
Materials and Methods: Plantar tests were conducted on adult S.D. rats of both sexes to examine intraplantar carrageenan-induced hyperalgesia. This was followed by an intrathecal (i.t.) injection of non-peptide OTR agonists, WAY 267,464 and TC OT 39, to assess their effects on hyperalgesia. Atosiban, an OTR antagonist, was also co-administered with these compounds to confirm their involvement in OTR activation.
Results: WAY 267,464 and TC OT 39 were both effective in ameliorating anti-hyperalgesia in male and female rats, suggesting no sex difference. Additionally, atosiban attenuated the anti-hyperalgesia effects of WAY 267,464 and TC OT 39, confirming these compounds’ involvement in OTR activation.
Conclusion: These compounds induced significant anti-hyperalgesia without any sex differences, suggesting that the inhibition of IRAP degradation eliminated the variation in oxytocin’s effects based on sex. Therefore, we propose these compounds as promising candidates for treating inflammatory hyperalgesia in clinical applications.

Keywords

Main Subjects

References

1. Lee HJ, Macbeth AH, Pagani JH, Young WS, 3rd. Oxytocin: The great facilitator of life. Prog Neurobiol 2009; 88: 127-151.
2. Xin Q, Bai B, Liu W. The analgesic effects of oxytocin in the peripheral and central nervous system. Neurochem Int 2017; 103: 57-64.
3. Condes-Lara M, Martinez-Lorenzana G, Rojas-Piloni G, Rodriguez-Jimenez J. Branched oxytocinergic innervations from the paraventricular hypothalamic nuclei to superficial layers in the spinal cord. Brain Res 2007; 1160: 20-29.
4. Breton JD, Veinante P, Uhl-Bronner S, Vergnano AM, Freund-Mercier MJ, Schlichter R, et al. Oxytocin-induced antinociception in the spinal cord is mediated by a subpopulation of glutamatergic neurons in lamina I-II, which amplify GABAergic inhibition. Mol Pain 2008; 4: 19-31.
5. Yu SQ, Lundeberg T, Yu LC. Involvement of oxytocin in spinal antinociception in rats with inflammation. Brain Res 2003; 983: 13-22.
6. Chow LH, Chen YH, Wu WC, Chang EP, Huang EY. Sex difference in oxytocin-induced anti-hyperalgesia at the spinal level in rats with intraplantar carrageenan-induced inflammation. PLoS One 2016; 11: e0162218-162233.
7. Chow LH, Chen YH, Lai CF, Lin TY, Chen YJ, Kao JH, et al. Sex difference of angiotensin IV-, LVV-hemorphin 7-, and oxytocin-induced antiallodynia at the spinal level in mice with neuropathic pain. Anesth Analg 2018; 126: 2093-2101.
8. Taylor SS, Noor N, Urits I, Paladini A, Sadhu MS, Gibb C, et al. Complex regional pain syndrome: A comprehensive review. Pain Ther 2021; 10: 875-892.
9. Jensen TS, Finnerup NB. Allodynia and hyperalgesia in neuropathic pain: clinical manifestations and mechanisms. Lancet Neurol 2014; 13: 924-935.
10. Li JH, Zhao SJ, Guo Y, Chen F, Traub RJ, Wei F, et al. Chronic stress induces wide-spread hyperalgesia: The involvement of spinal CCK(1) receptors. Neuropharmacology 2024; 258: 110067.
11. Yang J. Intrathecal administration of oxytocin induces analgesia in low back pain involving the endogenous opiate peptide system. Spine (Phila Pa 1976) 1994; 19: 867-871.
12. Condes-Lara M, Zayas-Gonzalez H, Manzano-Garcia A, Cordova-Quiroz E, Granados-Mortera J, Garcia-Cuevas M, et al. Successful pain management with epidural oxytocin. CNS Neurosci Ther 2016; 22: 532-534.
13. Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res 2008; 170: 473-512.
14. Hicks C, Jorgensen W, Brown C, Fardell J, Koehbach J, Gruber CW, et al. The nonpeptide oxytocin receptor agonist WAY 267,464: Receptor-binding profile, prosocial effects and distribution of c-Fos expression in adolescent rats. J Neuroendocrinol 2012; 24: 1012-1029.
15. Dannenhoffer CA, Kim EU, Saalfield J, Werner DF, Varlinskaya EI, Spear LP. Oxytocin and vasopressin modulation of social anxiety following adolescent intermittent ethanol exposure. Psychopharmacology (Berl) 2018; 235: 3065-3077.
16. Gannon RL. Non-peptide oxytocin receptor ligands and hamster circadian wheel running rhythms. Brain Res 2014; 1585: 184-190.
17. Hicks C, Ramos L, Reekie T, Misagh GH, Narlawar R, Kassiou M, et al. Body temperature and cardiac changes induced by peripherally administered oxytocin, vasopressin and the non-peptide oxytocin receptor agonist WAY 267,464: A biotelemetry study in rats. Br J Pharmacol 2014; 171: 2868-2887.
18. Hicks C, Ramos L, Reekie TA, Narlawar R, Kassiou M, McGregor IS. WAY 267,464, a non-peptide oxytocin receptor agonist, impairs social recognition memory in rats through a vasopressin 1A receptor antagonist action. Psychopharmacology (Berl) 2015; 232: 2659-2667.
19. Lahoud N, Maroun M. Oxytocinergic manipulations in corticolimbic circuit differentially affect fear acquisition and extinction. Psychoneuroendocrinology 2013; 38: 2184-2195.
20. Olszewski PK, Ulrich C, Ling N, Allen K, Levine AS. A non-peptide oxytocin receptor agonist, WAY-267,464, alleviates novelty-induced hypophagia in mice: Insights into changes in c-Fos immunoreactivity. Pharmacol Biochem Behav 2014; 124: 367-372.
21. Tang Y, Chen Z, Tao H, Li C, Zhang X, Tang A, et al. Oxytocin activation of neurons in ventral tegmental area and interfascicular nucleus of mouse midbrain. Neuropharmacology 2014; 77: 277-284.
22. Frantz MC, Rodrigo J, Boudier L, Durroux T, Mouillac B, Hibert M. Subtlety of the structure-affinity and structure-efficacy relationships around a nonpeptide oxytocin receptor agonist. J Med Chem 2010; 53: 1546-1562.
23. Pitt GR, Batt AR, Haigh RM, Penson AM, Robson PA, Rooker DP, et al. Non-peptide oxytocin agonists. Bioorg Med Chem Lett 2004; 14: 4585-4589.
24. Chow LH, Wu WC, Kuo CL, Hung HY, Chen YH, Pan W, et al. Estrogen can abolish oxytocin-induced spinal anti-hyperalgesia. Psychoneuroendocrinology 2022; 136: 105603.
25. Chow LH, Tao PL, Chen JC, Liao RM, Chang EP, Huang EY. A possible correlation between oxytocin-induced and angiotensin IV-induced anti-hyperalgesia at the spinal level in rats. Peptides 2013; 39: 21-28.
26. Chow LH, Huang EY, Ho ST, Lee TY, Tao PL. Dextromethorphan potentiates morphine antinociception at the spinal level in rats. Can J Anaesth 2004; 51: 905-910.
27. Cheng BC, Tao PL, Cheng YY, Huang EY. LVV-hemorphin 7 and angiotensin IV in correlation with antinociception and anti-thermal hyperalgesia in rats. Peptides 2012; 36: 9-16.
28. Manning M, Misicka A, Olma A, Bankowski K, Stoev S, Chini B, et al. Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. J Neuroendocrinol 2012; 24: 609-628.
29. Schorscher-Petcu A, Sotocinal S, Ciura S, Dupré A, Ritchie J, Sorge RE, et al. Oxytocin-induced analgesia and scratching are mediated by the vasopressin-1A receptor in the mouse. J Neurosci 2010; 30: 8274-8284.
30. Ring RH, Schechter LE, Leonard SK, Dwyer JM, Platt BJ, Graf R, et al. Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist. Neuropharmacology 2010; 58: 69-77.
31. Hilfiger L, Zhao Q, Kerspern D, Inquimbert P, Andry V, Goumon Y, et al. A nonpeptide oxytocin receptor agonist for a durable relief of inflammatory pain. Sci Rep 2020; 10: 3017-3027.
 
Iranian Journal of Basic Medical Sciences

Articles in Press, Accepted Manuscript
Available Online from 26 May 2025

Files

Share

How to cite

Statistics